Journal of Cancer Research and Therapeutics Close
 

Figure 5: (a) Induction of LNCaP cells by β-estradiol, testosterone, and dihydrotestosterone after 3-day treatment. Results expressed as mean ± standard deviation *P ≤ 0.05. (b) GI50 of FCX in prostate cancer cells after 10-nM β-estradiol/1-nM testosterone/1-nM dihydrotestosterone. Addition of testosterone/β-estradiol/dihydrotestosterone resulted in significant shift of GI50 indicating a protective effect over FCX by these steroids in prostate cancer cells

Figure 5: (a) Induction of LNCaP cells by β-estradiol, testosterone, and dihydrotestosterone after 3-day treatment. Results expressed as mean ± standard deviation *<i>P</i> ≤ 0.05. (b) GI<sub>50</sub> of FCX in prostate cancer cells after 10-nM β-estradiol/1-nM testosterone/1-nM dihydrotestosterone. Addition of testosterone/β-estradiol/dihydrotestosterone resulted in significant shift of GI<sub>50</sub> indicating a protective effect over FCX by these steroids in prostate cancer cells